title: The CEACAM1 tumor suppressor is an ATM and p53-regulated gene required for the induction of cellular senescence by DNA damage.
abstract: The p53 tumor-suppressor protein has a key role in the induction of cellular senescence, an important barrier to cancer development. However, very little is known about the physiological mediators of cellular senescence induced by p53. CEACAM1 is an immunoglobulin superfamily member whose expression is frequently lost in human tumors and exhibits tumor-suppressor features in several experimental systems, including Ceacam1 knockout mice. There is currently little understanding of the pathways and mechanisms by which CEACAM1 exerts its tumor-suppressor function. Here we report that CEACAM1 is strongly upregulated during the cellular response to DNA double-strand breaks (DSBs) starting from the lowest doses of DSB inducers used, and that upregulation is mediated by the ataxia telangiectasia mutated (ATM)/p53 pathway. Stable silencing of CEACAM1 showed that CEACAM1 is required for p53-mediated cellular senescence, but not initial cell growth arrest, in response to DNA damage. These findings identify CEACAM1 as a key component of the ATM/p53-mediated cellular response to DNA damage, and as a tumor suppressor mediating cellular senescence downstream of p53.
authors.affiliation: Clinique des Grangettes, Geneva, Switzerland.
authors.forename: A-P
authors.initials: AP
authors.lastname: Sappino
authors.forename: R
authors.initials: R
authors.lastname: Buser
authors.forename: Q
authors.initials: Q
authors.lastname: Seguin
authors.forename: M
authors.initials: M
authors.lastname: Fernet
authors.forename: L
authors.initials: L
authors.lastname: Lesne
authors.forename: F
authors.initials: F
authors.lastname: Gumy-Pause
authors.forename: W
authors.initials: W
authors.lastname: Reith
authors.forename: V
authors.initials: V
authors.lastname: Favaudon
authors.forename: S J
authors.initials: SJ
authors.lastname: Mandriota
references.citation: Genome Biol. 2002 Jun 18;3(7):RESEARCH0034
references.pmid: 12184808
references.citation: Biochimie. 1983 Nov-Dec;65(11-12):593-607
references.pmid: 6231960
references.citation: Curr Opin Genet Dev. 2009 Feb;19(1):25-31
references.pmid: 19181515
references.citation: Oncogene. 2005 Jan 20;24(4):697-705
references.pmid: 15580306
references.citation: Genome Biol. 2005;6(5):R43
references.pmid: 15892871
references.citation: Mol Carcinog. 1998 Nov;23(3):144-58
references.pmid: 9833775
references.citation: Med Sci (Paris). 2009 Mar;25(3):247-52
references.pmid: 19361387
references.citation: Curr Opin Cell Biol. 2006 Oct;18(5):565-71
references.pmid: 16919437
references.citation: J Biol Chem. 2008 Feb 1;283(5):2896-905
references.pmid: 18025081
references.citation: Nat Genet. 2006 Aug;38(8):873-5
references.pmid: 16832357
references.citation: Eur J Immunol. 2004 May;34(5):1322-32
references.pmid: 15114665
references.citation: Cancer Res. 2004 Dec 15;64(24):9152-9
references.pmid: 15604286
references.citation: Oncogene. 2006 Sep 7;25(40):5527-36
references.pmid: 16619040
references.citation: Science. 2004 Feb 6;303(5659):844-8
references.pmid: 14704432
references.citation: BMC Mol Biol. 2010 Nov 04;11:79
references.pmid: 21050451
references.citation: Science. 1998 Nov 20;282(5393):1497-501
references.pmid: 9822382
references.citation: Oncogene. 2006 Mar 9;25(10):1584-92
references.pmid: 16314843
references.citation: Curr Opin Cell Biol. 2010 Dec;22(6):816-27
references.pmid: 20807678
references.citation: Nat Immunol. 2001 Nov;2(11):1040-7
references.pmid: 11668339
references.citation: Nat Cell Biol. 2006 Aug;8(8):877-84
references.pmid: 16862142
references.citation: Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8467-72
references.pmid: 12077306
references.citation: Nat Rev Cancer. 2010 Jan;10(1):51-7
references.pmid: 20029423
references.citation: J Biol Chem. 2010 Apr 23;285(17):13092-106
references.pmid: 20177072
references.citation: Oncogene. 1990 Jun;5(6):893-9
references.pmid: 1694291